Latest Comments

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

Researchers raise hope for affordable malaria diagnostics

Researchers raise hope for affordable malaria diagnostics

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

China’s pharma market transformation to fuel global industry growth

China’s pharma market transformation to fuel global industry growth

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Pharma price hiking: why does it happen?

Pharma price hiking: why does it happen?

Targeting of specific patient groups to break into the epilepsy market

Targeting of specific patient groups to break into the epilepsy market

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Heading for the future: transplants and the pharma market

Heading for the future: transplants and the pharma market

Supernus Pharmaceuticals expands neurology portfolio with label extension of Trokendi XR

Supernus Pharmaceuticals expands neurology portfolio with label extension of Trokendi XR

PhRMA puts blame squarely on insurers in new drug spending report

PhRMA puts blame squarely on insurers in new drug spending report

Novo Nordisk’s Refixia: what are its prospects in the hemophilia B space?

Novo Nordisk’s Refixia: what are its prospects in the hemophilia B space?

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market

Inclisiran: a novel approach to targeting cholesterol and patient needs

Inclisiran: a novel approach to targeting cholesterol and patient needs

Trump’s new FDA Commissioner: A reasonable pick despite conflicts of interest

Trump’s new FDA Commissioner: A reasonable pick despite conflicts of interest

Novo Nordisk’s long-acting growth hormone somapacitan likely to conquer the adult GHD market in Japan

Novo Nordisk’s long-acting growth hormone somapacitan likely to conquer the adult GHD market in Japan

Newron Pharmaceuticals finally gets FDA approval for Parkinson’s medication

Newron Pharmaceuticals finally gets FDA approval for Parkinson’s medication

Trump’s budget: America first but Americans last

Trump’s budget: America first but Americans last

Toxicity, pricing, and combinatory strategies will drive competition amongst CDK4/6 Inhibitors

Toxicity, pricing, and combinatory strategies will drive competition amongst CDK4/6 Inhibitors

Gilead’s aggressive promotion of its TAF-based HIV portfolio already yielding results

Gilead’s aggressive promotion of its TAF-based HIV portfolio already yielding results